Comprehensive Report: An In-Depth Analysis of the First-in-Class Investigational Agent RRx-001 (Nibrozetone)

Executive Summary

RRx-001, also known by its International Nonproprietary Name (INN) nibrozetone, is a first-in-class, investigational small molecule therapeutic with a profoundly unconventional origin and a multifaceted mechanism of action that positions it uniquely within the landscape of modern drug development. Sourced from the aerospace and defense industry, this dinitroazetidine derivative represents a departure from traditional pharmaceutical discovery pipelines, a fact reflected in its complex, pleiotropic pharmacology.[1] The central and most compelling feature of RRx-001 is its paradoxical dual-action profile: it mediates targeted cytotoxicity in the tumor microenvironment while simultaneously conferring cytoprotection to healthy tissues.[1] This unique therapeutic window is the result of a context-dependent mechanism rooted in redox modulation.

The pharmacological activity of RRx-001 is extensive, defying the "one drug, one target" paradigm. Its primary mechanisms include potent, covalent inhibition of the NLRP3 inflammasome, a key driver of chronic inflammation; downregulation of the CD47-SIRPα immune checkpoint, which unmasks cancer cells for phagocytosis; and activation of the Nrf2 antioxidant pathway, which underpins its protective effects.[2] This is accomplished through a unique pharmacokinetic profile wherein the intravenously administered drug is rapidly sequestered by red blood cells, which then act as a "Trojan Horse" to deliver it specifically to the hypoxic tumor vasculature.[1] This delivery system minimizes systemic toxicity and is responsible for the drug's remarkably favorable safety profile, which is characterized by the absence of a maximum tolerated dose and a lack of systemic adverse events commonly associated with anticancer agents.[1]

The clinical development program, led by EpicentRx, Inc., strategically leverages this dual-action profile. The lead oncology indication, currently in a global Phase 3 trial (REPLATINUM), investigates RRx-001 as a chemosensitizing agent to reverse platinum resistance in third-line and beyond Small Cell Lung Cancer (SCLC).[8] Concurrently, a pivotal program in supportive care is evaluating RRx-001 for the prevention of severe oral mucositis (SOM) in head and neck cancer patients undergoing chemoradiation. This latter indication has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), highlighting the significant unmet medical need and the promising clinical data generated to date.[10]

Strategically, RRx-001 is being positioned as a foundational, combination-enabling agent with the potential to become a platform therapeutic. Its ability to enhance the efficacy of chemotherapy, radiation, and immunotherapy while mitigating their toxicities presents a compelling value proposition. While the complexity of its mechanism presents challenges for biomarker development and regulatory communication, its robust safety profile and promising clinical signals in both oncology and supportive care suggest that RRx-001 (nibrozetone) is a high-potential asset with the capacity to address a wide range of diseases linked by inflammation and oxidative stress.

Drug Profile: Chemical Identity and Unconventional Origins

Nomenclature and Chemical Identifiers

The investigational agent is identified by a series of names and codes that reflect its chemical nature, developmental history, and unique classification. A precise understanding of its nomenclature is foundational to analyzing its profile.

• Primary Investigational Name: The most commonly used identifier in clinical and preclinical literature is RRx-001.[12]
• International Nonproprietary Name (INN): In a significant regulatory milestone, the United States Adopted Name (USAN) Council, in consultation with the World Health Organization (WHO), granted the INN nibrozetone.[4] The assignment of a completely new generic name, rather than one fitting an existing class stem, formally recognizes RRx-001 as the first member of a new therapeutic class.[16] The name itself is a portmanteau derived from its key chemical features: nitro, bromine, and ketone, underscoring its unique structure.[16] This formal classification is a critical step toward commercialization, ensuring clear identification and preventing clinical confusion with other medications.[17]
• Chemical Acronyms: Early literature and chemical supply catalogs often refer to the molecule as ABDNAZ, an acronym for its chemical structure, either alpha bromodinitroazetidine or 1-bromoacetyl-3,3-dinitroazetidine.[4]
• Registry Numbers: For unambiguous identification in scientific databases and regulatory filings, the following identifiers are used:
• CAS Number: 925206-65-1 [10]
• DrugBank ID: DB12060 [10]
• UNII (Unique Ingredient Identifier): 7RPW6SU9SC [10]

Chemical Structure, Classification, and Properties

Nibrozetone (RRx-001) is a synthetic organic small molecule characterized by a novel and highly reactive chemical scaffold.

• IUPAC Name: The systematic chemical name is 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone.[10]
• Chemical Formula: $C_5H_6BrN_3O_5$.[14]
• Molecular Weight: The molecular weight is approximately 268.02 g/mol.[14]
• Classification: Chemically, RRx-001 is a dinitroazetidine derivative.[1] It belongs to the broader class of organic compounds known as tertiary carboxylic acid amides and is further characterized as an azetidine and a C-nitro compound.[20] Its structure is defined by two key pharmacophoric moieties: an electrophilic acyl bromide group and an energy-dense geminal dinitroazetidine group. These two components are connected via a stable amide linker, a design that has been conceptually compared to that of an antibody-drug conjugate.[1]
• Physical Properties: RRx-001 is described as a White to Off-white Solid.[18] It demonstrates solubility in common laboratory organic solvents, including dimethyl sulfoxide (DMSO), dimethylformamide (DMF), and ethanol.[14]

From Aerospace to Oncology: A Unique Discovery and Development Narrative

The origin story of RRx-001 is a radical departure from conventional drug discovery and is central to understanding its unique properties.

• Source of Discovery: RRx-001 was not the product of a target-based drug design program within a pharmaceutical company. Instead, it was identified following an extensive phenotypic screening of a library of chemical compounds sourced from the aerospace and defense industry.[1] This effort was the result of a unique partnership between academia, biotechnology, and ATK, an American aerospace and defense company.[1] The molecule itself is described as a derivative of rocket propellant, a class of materials engineered for high energy density and reactivity.[16] This unconventional starting point provided access to a vast and diverse library of small molecules with chemical structures and properties not typically found in pharmaceutical screening collections. The selection of RRx-001 for clinical advancement was based on an intriguing preclinical profile of both safety and activity.[21]
• Developer: The clinical development of RRx-001 is being led by EpicentRx, Inc., a privately held clinical-stage biotechnology company based in San Diego, California. The company was formerly known as RadioRx, Inc..[7]

The genesis of RRx-001 from aerospace materials is more than a trivial fact; it is the foundational determinant of its novel chemical structure and, consequently, its pleiotropic mechanism of action. Traditional drug discovery often begins with a specific biological target—such as a kinase or a receptor—and involves designing or screening for a molecule that binds to it with high specificity. In contrast, the discovery of RRx-001 appears to have been driven by a phenotypic screen, where compounds are tested for a desired biological effect without a priori knowledge of the target. High-energy materials like those used in propellants are, by their chemical nature, highly reactive and electrophilic. When introduced into a biological system, such compounds are predisposed to react with available nucleophiles, most notably the thiol groups on cysteine residues within proteins.[15] A screening process applied to such a library would therefore naturally select for molecules that are "promiscuous" in a controlled manner, capable of interacting with and modulating multiple biological pathways simultaneously, particularly those regulated by redox-sensitive proteins. This explains the emergence of a drug with a complex, multi-target profile rather than a highly specific, single-target agent. In essence, the origin of RRx-001 dictated its mechanism.

The Pleiotropic Pharmacology of RRx-001: A Multi-Targeting, Context-Dependent Mechanism of Action

The mechanism of action (MOA) of RRx-001 is exceptionally complex, operating through multiple, interconnected pathways that are highly dependent on the physiological context of the target tissue. It defies the traditional "one drug, one target" paradigm, functioning instead as a sophisticated modulator of the cellular microenvironment.

An Unconventional Paradigm: The "Shape-Shifting" Chimeric Molecule

RRx-001 is best understood as a "chimeric" or "shape-shifting" molecule, engineered to possess dual and seemingly contradictory functionalities within a single chemical entity.[15] Its structure amalgamates two distinct pharmacophores: the acyl bromide "targeting" moiety and the dinitroazetidine "payload" moiety.[15] The biological effect of the molecule is not static; it changes based on the local microenvironment. The targeting moiety is primarily responsible for its anti-inflammatory and antioxidant-inducing activities, which dominate in healthy, normoxic tissues. Conversely, the payload moiety is activated under specific conditions prevalent in diseased tissues like tumors—namely hypoxia and a high concentration of reducing agents (high hydrogen donation)—where it fragments to release a pro-inflammatory and pro-oxidant payload, including nitric oxide and other reactive species.[15] This intelligent design, which has been intentionally compared to that of an antibody-drug conjugate (ADC), allows RRx-001 to exert different, and even opposing, effects in cancerous versus normal tissues.[22]

Central Anti-Inflammatory Action: Potent and Covalent NLRP3 Inflammasome Inhibition

A central pillar of RRx-001's activity, particularly relevant to its cytoprotective effects, is its function as a potent and direct inhibitor of the NLRP3 inflammasome.[4] The NLRP3 inflammasome is a large intracellular protein complex that acts as a key sensor of cellular stress and danger, and its persistent activation is a fundamental driver of chronic inflammation across a wide spectrum of diseases.[27]

• Molecular Target and Mechanism: RRx-001 acts via a covalent, irreversible mechanism. The bromoacetyl group of the molecule functions as an electrophilic warhead that specifically targets and forms a stable thioether bond with the cysteine 409 (Cys409) residue located in the NACHT domain of the NLRP3 protein.[4] This covalent modification is critical, as it physically obstructs the interaction between NLRP3 and NEK7 (NIMA-related kinase 7), an essential binding event required for the oligomerization and assembly of the functional inflammasome complex.[4]
• Downstream Consequences: By preventing inflammasome assembly, RRx-001 effectively shuts down the entire downstream inflammatory cascade. It blocks the auto-catalytic activation of pro-caspase-1 into active caspase-1. This, in turn, prevents the proteolytic cleavage and maturation of the highly pro-inflammatory cytokines, interleukin-1β (IL-1β) and interleukin-18 (IL-18), and halts the initiation of pyroptosis, a lytic and inflammatory form of programmed cell death.[4] This potent anti-inflammatory action is the primary mechanism behind its efficacy in mitigating severe oral mucositis, a condition driven by intense inflammation in response to chemoradiation.[5]

Immune System Reprogramming: The "Erythrophagoimmunotherapeutic"

Beyond direct anti-inflammatory effects, RRx-001 profoundly remodels the tumor immune microenvironment, transforming it from an immunosuppressive to an immunostimulatory state. This has led to its characterization as an "erythrophagoimmunotherapeutic," a term reflecting its unique delivery via red blood cells and its reprogramming of phagocytic immune cells.[2]

• CD47-SIRPα Checkpoint Downregulation: A key action of RRx-001 is the downregulation of CD47 expression on the surface of tumor cells.[1] CD47 functions as a "don't eat me" signal that interacts with the SIRPα receptor on macrophages, protecting cancer cells from being engulfed and destroyed. The downregulation of CD47 by RRx-001 is an indirect effect, mediated through the inhibition of the MYC proto-oncogene, a known transcriptional regulator of the CD47 gene.[1] By reducing CD47 levels, RRx-001 effectively removes this protective shield, rendering tumor cells vulnerable to macrophage-mediated phagocytosis.
• Macrophage Repolarization: The tumor microenvironment is often dominated by tumor-associated macrophages (TAMs) of an M2 phenotype, which are immunosuppressive and promote tumor growth, angiogenesis, and metastasis. RRx-001 actively repolarizes these pro-tumor M2 TAMs into a pro-inflammatory, anti-tumor M1 phenotype.[1] This reprogramming is facilitated by the drug's unique delivery mechanism: RRx-001-bound red blood cells are preferentially phagocytosed by TAMs within the tumor, delivering the drug's active metabolites directly to these key immune cells and triggering their functional switch.[2]

Redox Modulation and Cytoprotection: Nrf2 Activation and Hypoxic Activity

The paradoxical ability of RRx-001 to be both cytotoxic to tumors and cytoprotective to normal tissues is explained by its sophisticated modulation of cellular redox balance.

• ROS/RNS Generation and Nrf2 Activation: RRx-001 is a pro-oxidant, generating reactive oxygen species (ROS) and reactive nitrogen species (RNS).[13] In the already redox-stressed environment of a tumor, this additional oxidative burden is sufficient to induce DNA damage, trigger apoptotic pathways (e.g., via p53 and PARP cleavage), and cause cell death.[13] However, in healthy tissues, this same pro-oxidant signal acts as a trigger for a powerful adaptive response. RRx-001 activates the master antioxidant transcription factor, Nuclear factor erythroid 2-related factor 2 (Nrf2).[5] It achieves this by covalently modifying a key cysteine residue on Keap1, the protein that sequesters Nrf2 in the cytoplasm. This modification disrupts the Keap1-Nrf2 complex, allowing Nrf2 to translocate to the nucleus and drive the transcription of a battery of cytoprotective genes, including antioxidant enzymes like HO-1 and NQO1.[13] This upregulation of the body's own defense mechanisms is the mechanistic basis for the protective effects of RRx-001 against the toxicities of chemotherapy and radiation.[1]
• Hypoxia-Activated Nitric Oxide (NO) Donation: RRx-001 is selectively activated in the hypoxic conditions that are a hallmark of solid tumors.[18] Under low oxygen tension, the dinitroazetidine "payload" moiety fragments, acting as a "superagonist" of nitric oxide (NO) generation.[1] This localized release of NO has several important anti-tumor effects. It causes vasodilation, which can normalize the chaotic tumor vasculature and improve blood flow.[2] This vascular normalization enhances the delivery of co-administered chemotherapeutic agents and increases tumor oxygenation, which in turn makes cancer cells more susceptible to radiation therapy. This dual function positions RRx-001 as both a chemosensitizer and a radiosensitizer.[13]

Epigenetic and Metabolic Disruption in Cancer Cells

In addition to its effects on the tumor microenvironment, RRx-001 also exerts direct anti-proliferative effects on cancer cells by disrupting their epigenetic regulation and metabolic machinery.

• Epigenetic Modulation: RRx-001 functions as a pan-epigenetic modulator. It has been shown to significantly decrease global DNA methylation in cancer cells by reducing the expression and enzymatic activity of DNA methyltransferases (DNMT1 and DNMT3a).[18] This demethylating activity can lead to the re-expression of silenced tumor suppressor genes and can also induce an interferon-like response through a phenomenon known as "viral mimicry," where the cell's machinery detects the abnormal demethylated DNA as if it were foreign.[2]
• Metabolic Targeting: RRx-001 directly interferes with cancer cell metabolism by inhibiting glucose-6-phosphate dehydrogenase (G6PD).[13] G6PD is the rate-limiting enzyme of the pentose phosphate pathway, which rapidly proliferating cancer cells rely on heavily for two critical functions: the production of NADPH to maintain redox balance and counteract oxidative stress, and the synthesis of ribonucleotides for DNA replication and repair. By inhibiting G6PD, RRx-001 simultaneously cripples the cancer cell's ability to manage oxidative stress and deprives it of the building blocks necessary for proliferation, creating a potent anti-tumor effect.[13]

The seemingly disparate mechanisms of RRx-001 can be understood through a single, unifying principle: it is a potent, context-dependent redox-modulating agent. Its ultimate biological effect—cytotoxic or cytoprotective—is dictated by the specific redox state and oxygenation level of the tissue it encounters. The molecule's core chemical reactivity is with the thiol groups on cysteine residues, which are critical regulatory sites on many of its key protein targets, including NLRP3 (Cys409), Keap1 (Cys151), and hemoglobin (βCys93).[2] In the relatively balanced redox environment of healthy, oxygenated tissue, the "microdoses" of ROS/RNS generated by RRx-001 act as a mild stressor or signaling event. This triggers a classic hormetic response: the activation of the powerful Nrf2 protective pathway, which fortifies the cell against subsequent, more severe insults (like chemotherapy or radiation).[1] In stark contrast, within the hypoxic, reducing, and already redox-stressed environment of a tumor, the molecule fragments and unleashes its full pro-oxidant payload.[16] This massive oxidative burst overwhelms the cancer cells' compromised antioxidant defenses—which are further weakened by RRx-001's inhibition of G6PD—pushing the cells past a point of no return and into apoptosis. Therefore, the drug's "paradox" is not a contradiction but a logical and elegant consequence of a single chemical property acting in two distinct biological contexts. This sophisticated mechanism is the source of its promising therapeutic window.

Pharmacokinetics, Administration, and Safety Profile

The pharmacokinetic properties of RRx-001 are as unconventional as its mechanism of action and are intrinsically linked to its unique safety and delivery profile. The drug's Absorption, Distribution, Metabolism, and Excretion (ADME) are dominated by its interaction with red blood cells.

A Unique ADME Profile: The Red Blood Cell as a "Trojan Horse"

RRx-001's behavior following intravenous administration is defined by its rapid sequestration within red blood cells (RBCs), which then function as a drug delivery vehicle.

• Absorption and Distribution: Upon entering the bloodstream via intravenous infusion, RRx-001, a nonpolar small molecule, rapidly crosses the RBC membrane.[1] Inside the cell, its highly electrophilic acyl bromide group irreversibly binds to available nucleophilic sulfhydryl groups, with a primary target being the β-cysteine 93 (βCys93) residue of hemoglobin.[1] This covalent conjugation effectively sequesters the drug within a subpopulation of RBCs, removing it from free circulation almost immediately post-injection.[1]
• Consequences of RBC Sequestration: This unique distribution mechanism has profound consequences. Firstly, it results in minimal systemic exposure to the free drug, which is the primary reason for its excellent safety profile. By shielding the drug from healthy tissues and vice versa, it prevents off-target interactions, including with cytochrome P450 enzymes, thereby minimizing the risk of drug-drug interactions.[1] Secondly, it facilitates targeted delivery to the tumor. The RRx-001-bound RBCs become more rigid and exhibit increased adherence to the abnormal, hypoxic endothelium of the tumor vasculature. These altered RBCs then accumulate in the tumor, acting as a "Trojan Horse" to deliver the drug and its metabolites precisely where they are needed.[1]
• Metabolism and Excretion: RRx-001 does not undergo conventional hepatic metabolism by drug-metabolizing enzymes.[6] Instead, its "metabolism" is a process of chemical decomposition that is activated by the hypoxic tumor microenvironment. Within the tumor, the drug fragments, releasing its active payloads, such as nitric oxide.[16] This unique behavior explains why early attempts in Phase 1 studies to measure the drug's pharmacokinetics by tracking its glutathione (GSH) adduct in plasma were found to be "not representative of exposure".[24] The true pharmacodynamics of the drug are dictated by the lifecycle of the drug-bound RBCs and their interactions within the tumor. The ultimate excretion pathways are not fully detailed, but clearance is presumed to be linked to the natural process of erythrophagocytosis, where aged or damaged RBCs are cleared by macrophages, a process that RRx-001 co-opts for its therapeutic effect within the tumor.

Systemic Distribution and Central Nervous System (CNS) Penetration

Despite the primary mechanism of RBC sequestration, RRx-001 and/or its active metabolites are capable of systemic distribution and, critically, are able to cross the blood-brain barrier (BBB).[15] This is a crucial property for a small molecule, as the BBB excludes the vast majority of therapeutic agents from the CNS. This permeability is essential for its clinical investigation in primary brain malignancies like glioblastoma and in the treatment of brain metastases, and it provides a strong rationale for its exploration in neurodegenerative diseases such as Parkinson's and ALS, where inflammation and oxidative stress in the CNS are key pathological drivers.[16]

Administration and Evolution of the Dosing Procedure

The method of RRx-001 administration has evolved during its clinical development to optimize tolerability.

• Route of Administration: RRx-001 is administered via intravenous (IV) infusion.[7]
• Evolution of the Procedure: Early Phase 1 studies utilizing direct IV infusion identified a consistent and dose-limiting adverse event: acute, transient, and often moderate-to-severe infusion-site pain, accompanied by venous inflammation (phlebitis), swelling, and vasodilation.[1] Mechanistic studies revealed that this reaction is caused by the rapid displacement of vasodilating nitric oxide from its binding site on hemoglobin (βCys93) as RRx-001 binds.[1] To address this tolerability issue, the administration protocol was intelligently redesigned. The current method involves an ex vivo incubation step. A small aliquot of the patient's own blood (approximately 12 mL) is drawn and mixed with the RRx-001 dose in a specialized device (such as the eLOOP Device) for about 10 minutes before being re-infused into the patient.[1] This allows the initial, rapid binding reaction to hemoglobin to occur in a controlled environment outside the body, thereby preventing the bolus release of NO in the patient's vein and significantly improving the tolerability of the infusion. This procedural innovation was a critical step that enabled the drug's continued development at therapeutically relevant doses.

Clinical Safety and Tolerability Profile

Across a dozen clinical trials involving over 400 patients, RRx-001 has demonstrated a remarkably favorable and consistent safety profile.

• Overall Safety: The drug is consistently described as well-tolerated and minimally toxic, both as a monotherapy and in combination with aggressive treatment regimens like chemotherapy and radiation.[1]
• Dose-Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD): In a significant departure from typical cytotoxic agents, no DLTs have been observed, and a formal MTD has not been reached in dose-escalation studies, even at doses as high as 83 mg/m².[1] The highest dose tested was deemed a "maximally feasible dose" based on the practical limitations of infusion time required to manage pain with the original direct IV method, a constraint that has since been resolved by the ex vivo procedure.[7]
• Adverse Event (AE) Profile: The AE profile of RRx-001 is notable for what it lacks. Systemic toxicities that are the hallmark of conventional anticancer therapies—such as myelosuppression, anemia, thrombocytopenia, severe gastrointestinal toxicity (nausea, vomiting, diarrhea), and nephrotoxicity—are conspicuously absent.[1] The most common drug-related AEs are the localized infusion-site reactions (pain, swelling, vein hardening) associated with the original administration method, which are now largely mitigated.[7] When used in combination, RRx-001 does not appear to add new safety signals or exacerbate the known toxicities of its partner agents; in fact, its clinical development is predicated on its ability to protect against them.[11]

Clinical Development and Trial Analysis

The clinical development program for RRx-001 is extensive and strategically designed to explore both its anticancer and cytoprotective properties across a range of indications. The program encompasses early-phase dose-finding studies, mid-stage signal-seeking trials, and late-stage pivotal studies, reflecting a maturing and ambitious development path.

The following table provides a consolidated overview of the key clinical trials that have defined the development trajectory of RRx-001. This summary serves as a strategic map, highlighting the indications, phases, statuses, and objectives of the most significant studies, which are analyzed in further detail in the subsequent sections.

Table 1: Comprehensive Summary of Key RRx-001 Clinical Trials

NCT ID	Trial Name/Acronym	Phase	Status	Indication(s)	Key Interventions	Summary of Findings/Objective
NCT03699956 / NCT05566041	REPLATINUM	3	Terminated / Active, Not Recruiting	Small Cell Lung Cancer (SCLC), 3rd line+	RRx-001 + Platinum Doublet (Cis/Carbo + Etoposide) vs. Platinum Doublet alone	To evaluate if RRx-001 can re-sensitize platinum-refractory SCLC to chemotherapy.8
NCT03515538	PREVLAR	2a	Completed	Head & Neck Cancer (Oral Mucositis)	RRx-001 + Standard CRT (Cisplatin + IMRT) vs. CRT alone	To assess safety and efficacy of RRx-001 in attenuating severe oral mucositis (SOM).5
NCT05966194	KEVLARx	2b/3	Recruiting	Head & Neck Cancer (Oral Mucositis)	RRx-001 vs. Placebo + Standard CRT	Pivotal trial following positive PREVLAR results to confirm SOM reduction.15
NCT02489903	QUADRUPLE THREAT	2	Active, Not Recruiting	SCLC, NSCLC, Neuroendocrine, Ovarian Cancer (Platinum-refractory)	RRx-001 followed by re-introduction of Platinum Doublet	To explore RRx-001's potential to sensitize various platinum-failed tumors.6
NCT02518958	PRIMETIME	1	Completed	Advanced Malignancies	RRx-001 + Nivolumab	To evaluate the safety and preliminary efficacy of combining RRx-001 with a PD-1 inhibitor.41
NCT02096354	ROCKET	2	Completed	Metastatic Colorectal Cancer (mCRC)	RRx-001 vs. Regorafenib	To compare the safety and activity of RRx-001 against standard of care in mCRC.6
NCT02871843	G-FORCE	1	Completed	Newly Diagnosed Glioblastoma (GBM) & Anaplastic Gliomas	RRx-001 + Radiation + Temozolomide	To evaluate safety and feasibility of adding RRx-001 to standard of care for GBM.6
NCT01359982 / NCT02215512	First-in-Human / Dose Escalation	1	Completed	Advanced Solid Tumors / Brain Metastases	RRx-001 monotherapy / RRx-001 + Whole Brain Radiation	To determine safety, tolerability, PK, and recommended Phase 2 dose.7
NCT02801097	PAYLOAD	1	Terminated	Advanced Cancer	RRx-001 + Irinotecan	To evaluate the combination of RRx-001 with irinotecan.12

Pivotal Indication: Small Cell Lung Cancer (SCLC) and the Chemosensitization Strategy

The lead oncology program for RRx-001 targets one of the most recalcitrant and aggressive malignancies, Small Cell Lung Cancer (SCLC). The therapeutic strategy is not to replace existing treatments but to overcome their primary limitation: acquired resistance. SCLC is defined by its initial high sensitivity to platinum-based chemotherapy, followed by an almost inevitable and rapid relapse with drug-resistant disease. RRx-001 is being developed as an "episensitizer," a novel agent designed to reverse this chemoresistance and restore tumor sensitivity to previously effective platinum doublet regimens in later lines of therapy.[9]

• QUADRUPLE THREAT (NCT02489903): This Phase 2 study was a critical "signal-seeking" trial that provided the foundational evidence for the SCLC program. It enrolled patients with various platinum-refractory tumor types, including a significant cohort of SCLC patients. In 26 heavily pretreated SCLC patients (median of 2 prior lines of therapy, 73% with platinum-resistant disease), treatment with RRx-001 followed by a re-challenge with a platinum-etoposide doublet yielded clinically meaningful results. The median overall survival (OS) from enrollment was 8.6 months, with an impressive 12-month OS rate of 44.1%.[50] The overall response rate (ORR) to the chemotherapy re-challenge was 26.9%, which included one complete response (CR) and six partial responses (PRs)—a notable outcome in a patient population for whom effective options are severely limited.[50] Furthermore, this trial identified a potential predictive biomarker: a decrease in programmed death-ligand 1 (PD-L1) expression on circulating tumor cells (CTCs) after RRx-001 treatment was found to be significantly correlated with clinical benefit from the subsequent chemotherapy.[31]
• REPLATINUM (NCT03699956 / NCT05566041): Based on the promising signals from QUADRUPLE THREAT, EpicentRx launched the global Phase 3 REPLATINUM trial. This randomized, controlled study is designed to provide definitive evidence of RRx-001's efficacy. It compares the combination of RRx-001 administered sequentially with a platinum doublet against a platinum doublet alone in patients with SCLC in the third-line setting or beyond.[8] The trial design incorporates a crossover provision, allowing patients in the control arm to receive the RRx-001 combination upon disease progression. While this feature can complicate the final OS analysis, it is an ethically sound design that enhances patient recruitment and retention.[9] The initial study (NCT03699956) was terminated and superseded by a new global study protocol (NCT05566041), suggesting a strategic refinement or expansion of the pivotal program.[8]

Supportive Care and Cytoprotection: A Paradigm Shift in Head and Neck Cancer

In parallel to its oncology program, EpicentRx is pursuing a distinct and highly promising indication in supportive care. This strategy capitalizes on the drug's paradoxical cytoprotective mechanisms—primarily its NLRP3 inflammasome inhibition and Nrf2 pathway activation—to address a severe and debilitating side effect of cancer therapy.[5] The target is severe oral mucositis (SOM), a painful and dose-limiting inflammation and ulceration of the mouth lining that frequently occurs in patients with head and neck cancer undergoing concurrent chemoradiation (CRT).

• PREVLAR (NCT03515538): This Phase 2a randomized trial provided the first clinical proof-of-concept for RRx-001's cytoprotective effects. The study demonstrated a statistically and clinically significant reduction in the duration of SOM in patients receiving RRx-001 alongside standard-of-care CRT. In the cohort of patients who developed SOM, the median duration was dramatically reduced from 24 days in the control arm to as low as 8.5 days in one of the RRx-001 treatment arms.[11] Crucially, the addition of RRx-001 was safe, with no new drug-related serious adverse events, and it did not interfere with the anti-tumor efficacy of the CRT regimen.[11] A secondary analysis of the PREVLAR data also suggested that RRx-001 may mitigate a "halo" of other related CRT toxicities, such as difficulty swallowing (dysphagia) and dry mouth (xerostomia), consistent with a systemic protective effect on irradiated tissues.[5]
• KEVLARx (NCT05966194): Following the successful results of PREVLAR, EpicentRx has initiated the pivotal KEVLARx trial. This larger, randomized, placebo-controlled Phase 2b/3 study is designed to definitively confirm the benefit of RRx-001 in reducing SOM and to provide the data necessary for a future regulatory submission for this indication.[15]

Combination Strategies and Early-Phase Development

The development program has also included several early-phase trials to explore RRx-001's potential in other indications and combinations, leveraging its diverse mechanisms of action.

• PRIMETIME (NCT02518958): This Phase 1 study explored the combination of RRx-001 with the anti-PD-1 immune checkpoint inhibitor nivolumab in patients with advanced malignancies. The rationale was to pair RRx-001's innate immune-stimulating properties (TAM repolarization via CD47 downregulation) with the adaptive immune T-cell activation of nivolumab. The combination was found to be safe and well-tolerated, with encouraging preliminary signs of efficacy, including a disease control rate (DCR) of 67% and an ORR of 25% in a heavily pretreated, multi-tumor population.[41]
• G-FORCE (NCT02871843): A completed Phase 1 study that tested the addition of RRx-001 to the standard Stupp protocol (radiation plus temozolomide) for newly diagnosed glioblastoma. This trial was designed to exploit RRx-001's ability to cross the blood-brain barrier and its potential as a radiosensitizer.[6]
• Other Exploratory Trials: Studies in metastatic colorectal cancer (ROCKET, NCT02096354), where RRx-001 was compared to regorafenib, and a Phase 1 trial in combination with irinotecan (PAYLOAD, NCT02801097) were either completed or terminated.[12] While these programs have not advanced to pivotal stages, they have contributed valuable safety and activity data to the overall understanding of the drug. The discontinuation of these specific paths likely reflects a strategic prioritization of the more promising SCLC and SOM indications.

The clinical development of RRx-001 reveals a sophisticated, dual-pronged strategy that effectively de-risks the asset. Rather than making a single, high-stakes bet on its success as an anticancer agent in a notoriously difficult indication like refractory SCLC, EpicentRx is simultaneously pursuing a supportive care indication. This is a strategically astute approach. The development path for supportive care agents can often be clearer and faster than for oncology drugs, particularly when the unmet need is high and the effect size is large, as appears to be the case for RRx-001 in SOM. The FDA's decision to grant Fast Track Designation for this indication validates this path and provides significant regulatory advantages that could shorten the time to a potential first approval.[10] Success in the SOM indication would not only address a critical patient need but would also provide EpicentRx with a revenue stream and market validation that could be used to fund the more ambitious and higher-risk SCLC program to completion. This represents a classic portfolio management strategy applied intelligently to a single, multifaceted molecule.

Regulatory Landscape and Commercial Strategy

The regulatory and commercial strategy for RRx-001 is focused on leveraging its unique clinical profile to secure market access, beginning with key designations in the United States and strategic partnerships for global reach.

U.S. Food and Drug Administration (FDA) Status

The primary regulatory engagement for RRx-001 has been with the U.S. FDA, where it has achieved a significant milestone for its supportive care program.

• Fast Track Designation: RRx-001 has been granted Fast Track Designation by the FDA for the prevention and attenuation of severe oral mucositis (SOM) associated with chemotherapy and radiation in patients with head and neck cancer.[10] This designation is a critical regulatory tool designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. The benefits of this status include more frequent interactions with the FDA review team, eligibility for Accelerated Approval and Priority Review if relevant criteria are met, and the option of a Rolling Review, where the company can submit completed sections of its New Drug Application (NDA) for review rather than waiting until the entire application is complete. This designation significantly enhances the prospects for a more efficient path to potential approval for the SOM indication.
• Expanded Access Program: For the REPLATINUM study in SCLC (NCT03699956), an expanded access program has been made available.[9] This allows patients with the serious or immediately life-threatening disease who are not eligible for the clinical trial to potentially gain access to the investigational drug, reflecting a commitment to addressing the high unmet need in this patient population.
• Regulatory Correspondence: It is noted that an FDA document from March 2024 identified "potential noncompliance" related to the completed Phase 2 ROCKET trial in metastatic colorectal cancer (NCT02096354).[54] While the specific details and resolution of this finding are not available in the provided materials, it represents a data point that would be subject to scrutiny in any formal due diligence process.

European Medicines Agency (EMA) Status

A thorough review of the provided information, including searches of the European Medicines Agency's public databases, indicates that there are currently no specific regulatory filings, special designations (such as the PRIME scheme), or marketing authorizations for RRx-001 or its generic name, nibrozetone, within the European Union.[56] This suggests that EpicentRx's regulatory strategy has, to date, been primarily concentrated on the U.S. market. Future engagement with the EMA would be a logical next step, particularly as the Phase 3 SCLC data matures.

Global Commercialization Strategy: The SciClone Partnership

To secure a foothold in a key global market and to fund ongoing development, EpicentRx has executed a significant regional partnership.

• Licensing Agreement: In July 2020, EpicentRx entered into an exclusive licensing agreement with SciClone Pharmaceuticals International Ltd..[23]
• Territory and Terms: The agreement grants SciClone the exclusive rights to co-develop and commercialize RRx-001 for cancer indications in the Greater China region, which includes mainland China, Hong Kong, Macau, and Taiwan. SciClone is responsible for all development, registration, and commercialization activities within these territories.[23]
• Financial Structure: Under the terms of the deal, EpicentRx received an undisclosed upfront payment. Furthermore, EpicentRx is eligible to receive up to $120 million in potential payments tied to the achievement of specific development, approval, and commercial milestones, in addition to double-digit royalties on net sales within the licensed territory.[23]
• Strategic Rationale: This partnership is a strategically sound move for a company of EpicentRx's size. It provides a significant source of non-dilutive funding to advance its global clinical programs. It also validates the RRx-001 asset through the commitment of an external partner and establishes a clear, expert-led path to commercialization in one of the world's largest and fastest-growing pharmaceutical markets. The deal effectively de-risks the development in that region by transferring the financial and logistical burden to a partner with local expertise.

The Fast Track Designation for the oral mucositis indication serves as the linchpin of EpicentRx's near-term regulatory and commercial strategy. This designation is not merely a procedural advantage; it is a clear signal from the FDA acknowledging the high unmet medical need for patients with head and neck cancer and the promising nature of the data from the Phase 2a PREVLAR trial. This supportive care indication likely represents the most direct and potentially fastest path to an initial market approval for RRx-001. Securing an approval for SOM would be a transformative event for the company, providing a source of revenue, validating the drug's safety and mechanism, and offering invaluable experience in navigating the path to commercialization. This initial success would substantially de-risk the company as a whole and strengthen its position to fund the more challenging and longer-term SCLC Phase 3 program to its conclusion. This is a well-considered strategy of building corporate value incrementally through a series of de-risked milestones.

Synthesis, Strategic Insights, and Future Directions

The RRx-001 Paradox Revisited: A Unified View of a Dual-Action Agent

The defining characteristic of RRx-001 is its paradoxical ability to be both cytotoxic to cancer cells and cytoprotective to normal tissues. This is not a contradiction but rather the outcome of a single, elegant principle: RRx-001 functions as a context-dependent redox modulator. Its biological effect is dictated by the specific physiological microenvironment it encounters. The molecule's fundamental chemical reactivity is targeted toward thiol groups on cysteine residues, which act as critical regulatory switches on numerous proteins. In the hypoxic, reducing, and oxidatively stressed environment of a tumor, RRx-001 unleashes a pro-oxidant payload that overwhelms the already compromised defense systems of cancer cells, pushing them into apoptosis. Conversely, in healthy, normoxic tissue, the mild pro-oxidant signal generated by the drug triggers a powerful, protective antioxidant response through the Nrf2 pathway. This hormetic effect pre-conditions normal cells, making them more resilient to subsequent damage from chemotherapy or radiation. This sophisticated mechanism creates an unusually wide therapeutic window, allowing for potent anti-tumor activity in the absence of significant systemic toxicity.

Strategic Implications of the Clinical Program: A Platform in a Pill

The clinical development strategy for RRx-001 astutely reflects its potential as a platform therapeutic. The company is pursuing two distinct but mechanistically linked paths to market. The SCLC program targets the high-risk, high-reward oncology market, aiming to address the critical challenge of chemoresistance. The oral mucositis program targets the lower-risk, high-unmet-need supportive care market, leveraging the drug's unique protective qualities. Success in either of these lead programs would provide strong validation for the underlying mechanism and open the door to numerous other indications. For example, a successful outcome in SOM would provide a strong rationale for trials investigating RRx-001's ability to protect against other treatment-related toxicities, such as chemotherapy-induced cardiotoxicity or cisplatin-induced nephrotoxicity, for which preclinical evidence exists.[27] Similarly, success in re-sensitizing SCLC to platinum agents would justify exploring the same strategy in other platinum-resistant tumors, such as ovarian or bladder cancer.

Challenges and Opportunities on the Path to Approval

Despite its promise, RRx-001 faces several challenges on its path to market, balanced by significant long-term opportunities.

• Challenges:
• Mechanistic Complexity: The drug's pleiotropic MOA is a scientific strength but a potential regulatory and marketing challenge. Communicating the value of a multi-target, context-dependent agent to regulatory bodies and clinicians accustomed to the "one drug, one target" model can be difficult. The development of a clear and effective biomarker strategy to identify patients most likely to benefit will be essential for its success.
• Competitive Landscape: The therapeutic areas targeted by RRx-001, particularly SCLC and immuno-oncology, are intensely competitive. RRx-001 will need to demonstrate not just activity, but a clear and significant clinical benefit over a growing number of existing and emerging therapies.
• Administration Procedure: While the ex vivo incubation method effectively resolves the infusion pain issue, it adds a layer of logistical complexity, time, and cost to the drug's administration compared to a standard IV infusion or an oral medication. This could be a potential barrier to widespread adoption if not managed effectively.
• Opportunities:
• Platform Expansion into Non-Oncology Indications: The potent anti-inflammatory (NLRP3 inhibition) and antioxidant-inducing (Nrf2 activation) properties of RRx-001, combined with its ability to cross the blood-brain barrier, create substantial opportunities outside of oncology. Its potential in neurodegenerative diseases is particularly compelling, and this is validated by grant funding from major foundations like The Michael J. Fox Foundation for Parkinson's research and FightMND for ALS research, indicating strong external scientific validation of this potential.[16]
• A Cornerstone for Combination Therapy: Perhaps the greatest opportunity for RRx-001 lies in its potential to become a cornerstone agent in combination therapy. Its excellent safety profile and its ability to modulate the tumor microenvironment to make it more susceptible to other treatments position it as an ideal partner for a wide array of therapeutic modalities, including conventional chemotherapy, radiation, targeted agents, and next-generation immunotherapies.

Concluding Remarks: An Expert Assessment of RRx-001

In conclusion, RRx-001 (nibrozetone) represents a high-risk, high-reward asset that is a true outlier in the pharmaceutical landscape. It breaks from convention in its aerospace origins, its paradoxical dual-action mechanism, and its bifurcated clinical development strategy. This paradoxical profile is its most compelling feature, enabling a de-risked path to market that simultaneously targets high-value indications in both oncology and supportive care. While significant clinical and regulatory hurdles remain, particularly for the ambitious goal of reversing chemoresistance in SCLC, the robust clinical data in severe oral mucositis, bolstered by an FDA Fast Track Designation, provides a tangible and potentially accelerated path to an initial market approval. The successful commercialization of RRx-001 for any indication would validate its novel platform. Ultimately, RRx-001 has the potential to become not just a single product, but a foundational therapeutic for treating a spectrum of diseases linked by the common pathologies of chronic inflammation and oxidative stress. Its improbable journey from a derivative of rocket propellant to a potential multi-indication medicine stands as a powerful testament to the value of unconventional and innovative approaches to drug discovery and development.

Works cited

1. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development | Journal of Medicinal Chemistry - ACS Publications, accessed October 16, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00599
2. RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic" - PubMed Central, accessed October 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7790525/
3. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development | Journal of Medicinal Chemistry - ACS Publications, accessed October 16, 2025, https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.1c00599
4. nibrozetone | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 16, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13184
5. RRx-001 Affects Multiple Toxicities in Patients Receiving Concomitant Chemoradiation for Head and Neck Cancers: Observations of the PREVLAR Phase II Trial | JCO Oncology Advances - ASCO Publications, accessed October 16, 2025, https://ascopubs.org/doi/10.1200/OA.24.00021
6. Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trials - PubMed Central, accessed October 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9548015/
7. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study - PubMed, accessed October 16, 2025, https://pubmed.ncbi.nlm.nih.gov/26296952/
8. RRx-001 Active Not Recruiting Phase 3 Trials for Small Cell Lung Cancer (SCLC) Treatment, accessed October 16, 2025, https://go.drugbank.com/drugs/DB12060/clinical_trials?conditions=DBCOND0048944&phase=3&purpose=treatment&status=active_not_recruiting
9. Study Details | NCT03699956 | RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer | ClinicalTrials.gov, accessed October 16, 2025, https://clinicaltrials.gov/study/NCT03699956
10. Nibrozetone - Wikipedia, accessed October 16, 2025, https://en.wikipedia.org/wiki/Nibrozetone
11. FDA Grants Fast Track Designation to RRx-001 for Severe Oral ..., accessed October 16, 2025, https://www.onclive.com/view/fda-grants-fast-track-designation-to-rrx-001-for-severe-oral-mucositis-in-head-and-neck-cancer
12. Advanced Cancer Terminated Phase 1 Trials for RRx-001 (DB12060) | DrugBank Online, accessed October 16, 2025, https://go.drugbank.com/indications/DBCOND0030464/clinical_trials/DB12060?phase=1&status=terminated
13. RRx-001 | Dehydrogenase inhibitor | Mechanism | Concentration - Selleck Chemicals, accessed October 16, 2025, https://www.selleckchem.com/products/rrx-001.html
14. RRX-001 | CAS#925206-65-1 | Radiosensitizing agent | MedKoo Biosciences, accessed October 16, 2025, https://www.medkoo.com/products/5812
15. RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist - Frontiers, accessed October 16, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1204143/full
16. Therapeutic frontiers: the potential of RRx-001 and AdAPT-001 - Drug Target Review, accessed October 16, 2025, https://www.drugtargetreview.com/article/111290/therapeutic-frontiers-the-potential-of-rrx-001-and-adapt-001/
17. United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee Recognizes New Therapeutic Class by Granting "nibrozetone" as New Generic Name for EpicentRx's Lead Small Molecule NLRP3 Inhibitor, RRx-001 - PR Newswire, accessed October 16, 2025, https://www.prnewswire.com/news-releases/united-states-adopted-name-usan-council-and-international-nonproprietary-names-inn-expert-committee-recognizes-new-therapeutic-class-by-granting-nibrozetone-as-new-generic-name-for-epicentrxs-lead-small-molecule-nlrp3-inhib-301871261.html
18. CAS 925206-65-1 RRX-001 - BOC Sciences, accessed October 16, 2025, https://www.bocsci.com/product/rrx-001-cas-925206-65-1-462775.html
19. RRx-001 (ABDNAZ, CAS Number: 925206-65-1) | Cayman Chemical, accessed October 16, 2025, https://www.caymanchem.com/product/28846/rrx-001
20. RRx-001: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 16, 2025, https://go.drugbank.com/drugs/DB12060
21. On the Origin of RRx-001 - EpicentRx, accessed October 16, 2025, https://www.epicentrx.com/blog/on-the-origin-of-rrx-001/
22. RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist - PubMed, accessed October 16, 2025, https://pubmed.ncbi.nlm.nih.gov/37313460/
23. EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing ..., accessed October 16, 2025, https://www.epicentrx.com/press-release/epicentrx-inc-and-sciclone-pharmaceuticals-establish-licensing-agreement-for-rrx-001-in-greater-china-2/
24. A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent. | Journal of Clinical Oncology - ASCO Publications, accessed October 16, 2025, https://ascopubs.org/doi/10.1200/jco.2014.32.15_suppl.2578
25. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity, accessed October 16, 2025, https://www.oncotarget.com/article/6526/text/
26. RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist - PubMed Central, accessed October 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10258348/
27. A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation - PMC - PubMed Central, accessed October 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10015535/
28. (PDF) A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation - ResearchGate, accessed October 16, 2025, https://www.researchgate.net/publication/369268144_A_Review_of_RRx-001_A_Late-Stage_Multi-Indication_Inhibitor_of_NLRP3_Activation_and_Chronic_Inflammation
29. An RRx-001 Analogue With Potent Anti-NLRP3 Inflammasome Activity but Without High-Energy Nitro Functional Groups - Frontiers, accessed October 16, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.822833/full
30. Full article: RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic" - Taylor & Francis Online, accessed October 16, 2025, https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1746172
31. In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit, accessed October 16, 2025, https://tlcr.amegroups.org/article/view/46924/html
32. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials - PubMed, accessed October 16, 2025, https://pubmed.ncbi.nlm.nih.gov/27935336/
33. The Hypoxia-Selective Epigenetic Agent, Rrx-001, Triggers Apoptosis and Overcomes Drug-Resistance in Multiple Myeloma Cells | Blood | American Society of Hematology, accessed October 16, 2025, https://ashpublications.org/blood/article/126/23/918/136555/The-Hypoxia-Selective-Epigenetic-Agent-Rrx-001
34. RRx-001 (Nibrozetone) | Radiosensitizer/CD47 and SIRP-α Inhibitor | MedChemExpress, accessed October 16, 2025, https://www.medchemexpress.com/RRx-001.html
35. (PDF) Safety and activity of RRx-001 in patients with advanced cancer: A first-in-human, open-label, dose-escalation phase 1 study - ResearchGate, accessed October 16, 2025, https://www.researchgate.net/publication/281166753_Safety_and_activity_of_RRx-001_in_patients_with_advanced_cancer_A_first-in-human_open-label_dose-escalation_phase_1_study
36. RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist. - eScholarship.org, accessed October 16, 2025, https://escholarship.org/uc/item/5nv5p20v
37. RRx-001 Completed Phase 1 Trials for Oligodendroglioma / Glioblastomas / Anaplastic Oligodendroglioma (AO) Treatment | DrugBank Online, accessed October 16, 2025, https://go.drugbank.com/drugs/DB12060/clinical_trials?conditions=DBCOND0052374%2CDBCOND0043840%2CDBCOND0002896&phase=1&purpose=treatment&status=completed
38. RRx-001 Completed Phase 1 Trials for Brain Metastases Treatment | DrugBank Online, accessed October 16, 2025, https://go.drugbank.com/drugs/DB12060/clinical_trials?conditions=DBCOND0029546&phase=1&purpose=treatment&status=completed
39. EpicentRx To Present Nibrozetone (RRx-001) Data on Parkinson's Disease and ALS/MND at Neuroscience 2023 - PR Newswire, accessed October 16, 2025, https://www.prnewswire.com/news-releases/epicentrx-to-present-nibrozetone-rrx-001-data-on-parkinsons-disease-and-alsmnd-at-neuroscience-2023-301977379.html
40. Patent and Marketing Exclusivities 101 for Drug Developers - Semantic Scholar, accessed October 16, 2025, https://pdfs.semanticscholar.org/4b38/d1c538ceb3eb83195d710802af2af1abe401.pdf
41. Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME) - Frontiers, accessed October 16, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1104753/full
42. RRx-001 Terminated Phase 3 Trials for Small Cell Lung Cancer (SCLC) Treatment, accessed October 16, 2025, https://go.drugbank.com/drugs/DB12060/clinical_trials?conditions=DBCOND0048944&phase=3&purpose=treatment&status=terminated
43. Study Details | NCT03515538 | Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers | ClinicalTrials.gov, accessed October 16, 2025, https://clinicaltrials.gov/study/NCT03515538
44. Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers - larvol clin, accessed October 16, 2025, https://clin.larvol.com/trial-detail/NCT03515538
45. Study Details | NCT05966194 | RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer | ClinicalTrials.gov, accessed October 16, 2025, https://clinicaltrials.gov/study/NCT05966194
46. RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) - Stanford Health Care, accessed October 16, 2025, https://stanfordhealthcare.org/trials/r/NCT02489903.html
47. RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) - Clinical Trials | Stanford Medicine, accessed October 16, 2025, https://clinicaltrials.stanford.edu/trials/r/NCT02489903.html
48. Effect of RRx-001 on nephrotoxicity of cisplatin/etoposide in patients with solid tumors., accessed October 16, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.6_suppl.657
49. Clinical Trial: NCT02489903 - My Cancer Genome, accessed October 16, 2025, https://www.mycancergenome.org/content/clinical_trials/NCT02489903/
50. Multicenter phase II trial of RRx-001 in previously treated SCLC ..., accessed October 16, 2025, https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.e20104
51. Phase 1 pilot study of RRx-001 + nivolumab in patients with ..., accessed October 16, 2025, https://pubmed.ncbi.nlm.nih.gov/36960054/
52. Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME) - ResearchGate, accessed October 16, 2025, https://www.researchgate.net/publication/369071282_Phase_1_pilot_study_of_RRx-001_nivolumab_in_patients_with_advanced_metastatic_cancer_PRIMETIME
53. RRx-001 Completed Phase 2 Trials for Colorectal Neoplasms Treatment | DrugBank Online, accessed October 16, 2025, https://go.drugbank.com/drugs/DB12060/clinical_trials?conditions=DBCOND0028207&phase=2&purpose=treatment&status=completed
54. EpicentRx Inc. Re: Submission of Clinical Trial Results Information Pursuant to 42 U.S.C. 282(j) - FDA, accessed October 16, 2025, https://www.fda.gov/media/177628/download
55. NCT01359982 | Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects | ClinicalTrials.gov, accessed October 16, 2025, https://clinicaltrials.gov/study/NCT01359982
56. PRIME: priority medicines | European Medicines Agency (EMA) - European Union, accessed October 16, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines
57. What's new | European Medicines Agency (EMA), accessed October 16, 2025, https://www.ema.europa.eu/en/news-events/whats-new
58. Rozlytrek | European Medicines Agency (EMA), accessed October 16, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek
59. European Medicines Agency (EMA), accessed October 16, 2025, https://www.ema.europa.eu/en/medicines
60. European Medicines Agency - European Union, accessed October 16, 2025, https://www.ema.europa.eu/en/homepage
61. National registers of authorised medicines | European Medicines Agency (EMA), accessed October 16, 2025, https://www.ema.europa.eu/en/medicines/national-registers-authorised-medicines
62. Research and development | European Medicines Agency (EMA), accessed October 16, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/research-development